- Close date
- Tuesday, 28 February 2023
- Academic background
- Health Sciences
- Host campus
- PhD, Master's
- Pathology (Dunedin)
- Dr Heather Cunliffe
The cell surface cytokine receptor Fn14 (TNRFSF12A) and it's cytokine ligand TWEAK, are known to promote malignant progression and reduce survival rates in several solid tumours, including Glioblastoma, and cancers of the breast, kidney, ovary, prostate and esophagus.
Mechanisms leading to aberrant activation of the Fn14/TWEAK signaling axis are poorly understood. Characterising these mechanisms will provide new insight into reducing or halting cellular migration and invasion of Fn14-positive cancers.
This project will investigate genetic, epigenetic, genomic, transcriptomic and cellular factors controlling Fn14/TWEAK expression in laboratory models of malignant progression, and validation studies in archival patient samples.
ContactDr Heather Cunliffe
Similar research opportunities
- A phoenix from the ashes: Do dying cancer cells induce drug-tolerance in lung cancer?
- A role for untranslated p53 mRNA in drug resistance
- Characterisation of YB-1 interactions with the cytoskeleton using live cell imaging
- Comprehensive characterization of uncommon TP53 mutations in cancer
- Evaluation of novel multitargeted therapeutic possibilities in ovarian cancer